BioLineRx Ltd (NASDAQ:BLRX) Q4 2018 Earnings Conference Call - Final Transcript
Mar 28, 2019 • 10:00 am ET
Ladies and gentlemen, thank you for standing by. Welcome to the BioLineRx Fourth Quarter and Full Year 2018 Results Conference Call. All participants are at present in a listen-only mode. Following the management's formal presentation, instructions will be given for the question-and-answer session. (Operator Instructions)
I would now like to turn over the call to Timothy McCarthy of LifeSci Advisors to read the Safe Harbor statement. Tim, please go ahead.
Thank you, operator. Before turning the call over to management, I would like to make the following remarks concerning forward-looking statements. All statements in this conference call other than historical facts are indeed forward-looking statements. The words anticipate, believe, estimate, expect, intend, guidance, confidence, target, project and other similar expressions are used typically to identify such forward-looking statements.
These forward-looking statements are not guarantees of future performance and may involve and are subject to certain risks and uncertainties and other factors that may affect BioLineRx's business, financial condition and other operating results. These include, but are not limited to the risk factors and other qualifications contained in BioLineRx's annual report on Form 20-F, quarterly reports filed in a 6-K and other reports filed by BioLineRx with the SEC to which your attention is directed. Actual outcomes and results may differ materially from what is expressed or implied by these forward-looking statements. BioLineRx expressly disclaims any intent or obligation to update these forward-looking statements.
At this time, it is now my pleasure to turn the call over to Mr. Phil Serlin, Chief Executive Officer of BioLineRx.
Philip A. Serlin
Thank you, Tim and good morning, everyone. Thank you for joining us on our fourth quarter earnings conference call today. Earlier this morning, we issued our Q4 earnings press release, a copy of which is available in the investor relations section of our website. It was also filed as a 6-K.
Our agenda this morning is as follows, we will begin with a review of our programs and activities, enumerate our major target milestones over the next few quarters, and then Mali Zeevi, our Chief Financial Officer will provide a short discussion of our financial results. We will then open up the call to your questions. Also joining the call today for Q&A are Abi Vainstein, Vice President Clinical Development; and Ella Sorani, Vice President of Research and Development.
During the fourth quarter, we made notable progress advancing our therapeutic candidates BL-8040 and AGI-134 that we are developing both independently and in collaboration with others for the treatment of multiple cancer indications. Beginning with 8040, for those of you who may be new to the BioLineRx story, BL-8040 is a novel short peptide that functions as a high affinity antagonist to CXCR-4, a chemokine receptor whose over expression has been implicated in the progression of over 70% of all cancers.
We are evaluating BL-8040 in eight Phase II or Phase III clinical trials in multiple oncology indications, including stem cell mobilization for multiple myeloma patients, acute myeloid leukemia and pancreatic cancer. One of these trials is